File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: COMT (Val 158/108Met) genotype moderates the impact ofantipsychotic medication on verbal IQ in twins with schizophrenia

TitleCOMT (Val 158/108Met) genotype moderates the impact ofantipsychotic medication on verbal IQ in twins with schizophrenia
Authors
Keywordscatechol-O-methyl transferase
cognition
endophenotypes
intelligence quotient
schizophrenia
Issue Date2011
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.psychgenetics.com
Citation
Psychiatric Genetics, 2011, v. 21 n. 2, p. 98-105 How to Cite?
AbstractOBJECTIVES: In this study, we aimed to assess the moderating effects of the catechol-O-methyl transferase (COMT) (ValMet) genotype on antipsychotic medication-induced changes in the cognitive performance of patients with chronic schizophrenia. METHODS: The sample consisted of 85 monozygotic and53dizygotic twin pairs, of varying concordance for schizophrenia, and healthy control twins. Cognitive abilitywas measured using the Wechsler Adult Intelligence Scale-third edition. We used structural equation modelling to estimate main and interaction effects of the COMT status and antipsychotic medication dose on verbal intelligence quotient (VIQ) and performance intelligence quotient scores. RESULTS: There was no evidence of a main or interaction effect of the COMT status or chlorpromazine equivalent dose on the performance intelligence quotient. There were no main effects of COMT or chlorpromazine equivalent dose on VIQ; however, there was evidence of a statistically significant interaction (P<0.01) between the COMT andchlorpromazine equivalents on VIQ. The VIQ performance ofval/val individuals was significantly lower with increasing antipsychotic medication dose, up to 12 intelligence quotient points lower than met carriers treated with medication. Intheabsence of medication, the three genotypes did not significantly differ, whereas at the highest doses (1500), the val/val homozygotes and Met carriers differed by morethan one standard deviation. CONCLUSION: Our results show that the verbal abilities ofval homozygotes of the COMT gene are cognitively impaired by higher doses of antipsychotic medication. Thisassociation is reversed in Met carriers. These data areconsistent with an earlier study that found evidence ofmoderating effects of antipsychotic medication onN-back and verbal fluency tasks. © 2011 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/141818
ISSN
2023 Impact Factor: 1.5
2023 SCImago Journal Rankings: 0.629
ISI Accession Number ID
Funding AgencyGrant Number
European Community through a Marie Curie Training Network
NARSAD
Pfizer
Janssen-Cilag
Eli Lily
Funding Information:

This work was supported by the European Community's Sixth Framework Programme through a Marie Curie Training Network called the European Twin Study Network on Schizophrenia (EUTwinsS), and NARSAD (through a Young Investigator Award to Dr Timothea Toulopoulou). Timothea Toulopoulou, Irene Rebollo Mesa and Marco Picchioni had full access to all the data in the study and to take responsibility for the integrity of the data and the accuracy of the data analysis. Professor Murray received honoraria for lectures from Astra-Zeneca, Janssen, Lilly and BMS. Dr Picchioni has received travel awards from Pfizer, Janssen-Cilag, and Eli Lily. Drs Toulopoulou, Rebollo Mesa, Bramon and Miss Shaikh report no competing interests.

References

 

DC FieldValueLanguage
dc.contributor.authorRebolloMesa, Ien_HK
dc.contributor.authorPicchioni, Men_HK
dc.contributor.authorShaikh, Men_HK
dc.contributor.authorBramon, Een_HK
dc.contributor.authorMurray, Ren_HK
dc.contributor.authorToulopoulou, Ten_HK
dc.date.accessioned2011-09-27T03:02:33Z-
dc.date.available2011-09-27T03:02:33Z-
dc.date.issued2011en_HK
dc.identifier.citationPsychiatric Genetics, 2011, v. 21 n. 2, p. 98-105en_HK
dc.identifier.issn0955-8829en_HK
dc.identifier.urihttp://hdl.handle.net/10722/141818-
dc.description.abstractOBJECTIVES: In this study, we aimed to assess the moderating effects of the catechol-O-methyl transferase (COMT) (ValMet) genotype on antipsychotic medication-induced changes in the cognitive performance of patients with chronic schizophrenia. METHODS: The sample consisted of 85 monozygotic and53dizygotic twin pairs, of varying concordance for schizophrenia, and healthy control twins. Cognitive abilitywas measured using the Wechsler Adult Intelligence Scale-third edition. We used structural equation modelling to estimate main and interaction effects of the COMT status and antipsychotic medication dose on verbal intelligence quotient (VIQ) and performance intelligence quotient scores. RESULTS: There was no evidence of a main or interaction effect of the COMT status or chlorpromazine equivalent dose on the performance intelligence quotient. There were no main effects of COMT or chlorpromazine equivalent dose on VIQ; however, there was evidence of a statistically significant interaction (P<0.01) between the COMT andchlorpromazine equivalents on VIQ. The VIQ performance ofval/val individuals was significantly lower with increasing antipsychotic medication dose, up to 12 intelligence quotient points lower than met carriers treated with medication. Intheabsence of medication, the three genotypes did not significantly differ, whereas at the highest doses (1500), the val/val homozygotes and Met carriers differed by morethan one standard deviation. CONCLUSION: Our results show that the verbal abilities ofval homozygotes of the COMT gene are cognitively impaired by higher doses of antipsychotic medication. Thisassociation is reversed in Met carriers. These data areconsistent with an earlier study that found evidence ofmoderating effects of antipsychotic medication onN-back and verbal fluency tasks. © 2011 Lippincott Williams & Wilkins, Inc.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.psychgenetics.comen_HK
dc.relation.ispartofPsychiatric Geneticsen_HK
dc.subjectcatechol-O-methyl transferaseen_HK
dc.subjectcognitionen_HK
dc.subjectendophenotypesen_HK
dc.subjectintelligence quotienten_HK
dc.subjectschizophreniaen_HK
dc.titleCOMT (Val 158/108Met) genotype moderates the impact ofantipsychotic medication on verbal IQ in twins with schizophreniaen_HK
dc.typeArticleen_HK
dc.identifier.emailToulopoulou, T:timothea@hku.hken_HK
dc.identifier.authorityToulopoulou, T=rp01542en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/YPG.0b013e32834371a7en_HK
dc.identifier.pmid21233783-
dc.identifier.scopuseid_2-s2.0-79952704252en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952704252&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue2en_HK
dc.identifier.spage98en_HK
dc.identifier.epage105en_HK
dc.identifier.isiWOS:000287841700006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridRebolloMesa, I=22935342500en_HK
dc.identifier.scopusauthoridPicchioni, M=6507443795en_HK
dc.identifier.scopusauthoridShaikh, M=24377053800en_HK
dc.identifier.scopusauthoridBramon, E=8089378900en_HK
dc.identifier.scopusauthoridMurray, R=35406239400en_HK
dc.identifier.scopusauthoridToulopoulou, T=8855468700en_HK
dc.identifier.issnl0955-8829-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats